• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    LFW Photonics Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Alpha Tau Medical Ltd. - Warrant (NQ:DRTSW)

    1.120 +0.020 (+1.82%)
    Streaming Delayed Price Updated: 3:57 PM EST, Feb 20, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    All News about Alpha Tau Medical Ltd. - Warrant

    < Previous 1 2 Next >
    News headline image
    Alpha Tau Reports New Positive Results in Two Upcoming Presentations at ASCO GI 2026 Symposium Showcasing Immune-Preservation and High Disease Control in Montreal Pancreatic Cancer Alpha DaRT® Study
    From Alpha Tau Medical Ltd.
    Via GlobeNewswire
    News headline image
    Alpha Tau Submits First Pre-Market Approval Module to the FDA for Alpha DaRT® for the Treatment of Recurrent Cutaneous Squamous Cell Carcinoma (cSCC)
    From Alpha Tau Medical Ltd.
    Via GlobeNewswire
    News headline image
    Alpha Tau Successfully Treats First Patient in its U.S. Trial for Patients with Recurrent Glioblastoma at the James Cancer Hospital at The Ohio State University
    From Alpha Tau Medical Ltd.
    Via GlobeNewswire
    News headline image
    Alpha Tau Announces Presentation of Two Alpha DaRT Pancreatic Cancer Abstracts at Upcoming 2026 ASCO GI Symposium
    Pancreatic cancer multi-center clinical trial in U.S. is underway; patient recruitment expected to be completed by the end of Q1 2026 
    From Alpha Tau Medical Ltd.
    Via GlobeNewswire
    News headline image
    Alpha Tau Receives FDA Approval to Initiate a Trial for Patients with Locally Recurrent Prostate Cancer
    - FDA approval marks Alpha Tau’s fifth simultaneous active U.S. IDE as the Company expands Alpha DaRT’s reach into recurrent prostate cancer - 
    From Alpha Tau Medical Ltd.
    Via GlobeNewswire
    News headline image
    Alpha Tau Announces Receipt of Radioactive Material License for its New Hampshire Manufacturing Facility, Advancing Towards Commercial Readiness
    From Alpha Tau Medical Ltd.
    Via GlobeNewswire
    News headline image
    Alpha Tau Successfully Treats First Patient in its U.S. Multi-Center Pancreatic Cancer Clinical Trial
    From Alpha Tau Medical Ltd.
    Via GlobeNewswire
    News headline image
    Alpha Tau Announces Closing of $36.9 Million Registered Direct Offering and Strategic Marketing Alliance with Oramed Pharmaceuticals
    Investment comes at a pivotal moment for Alpha Tau, which is experiencing remarkable growth on multiple fronts, with four active U.S. trial approvals, expansion into multiple internal organ... 
    From Alpha Tau Medical Ltd.
    Via GlobeNewswire
    News headline image
    Alpha Tau Receives FDA Approval to Initiate a Trial for Patients with Recurrent Glioblastoma
    From Alpha Tau Medical Ltd.
    Via GlobeNewswire
    News headline image
    Alpha Tau Receives Medical Device Single Audit Program (MDSAP) Certification
    From Alpha Tau Medical Ltd.
    Via GlobeNewswire
    News headline image
    Alpha Tau Announces FDA Approval of IDE Supplement to Expand Pilot Trial of Alpha DaRT® to Thirty Patients with Pancreatic Cancer in Two Cohorts, with Locally Advanced or Metastatic Disease
    From Alpha Tau Medical Ltd.
    Via GlobeNewswire
    News headline image
    Alpha Tau Announces Cornerstone Interim Data Across Multiple Clinical Trials to be Shared at R&D Update Day
    From Alpha Tau Medical Ltd.
    Via GlobeNewswire
    News headline image
    Alpha Tau Announces Upcoming Presentation of New Data at 2025 ASCO GI Symposium and at Company R&D Update Day
    From Alpha Tau Medical Ltd.
    Via GlobeNewswire
    News headline image
    Alpha Tau Announces Appointment of Maya Netser to its Board of Directors; Board Member Meir Jakobsohn Stepping Down, Staying on as Advisor
    From Alpha Tau Medical Ltd.
    Via GlobeNewswire
    News headline image
    Alpha Tau Announces Acceptance Into FDA’s Total Product Life Cycle Advisory Program to Accelerate Market Access to Alpha DaRT® for Patients with Recurrent Glioblastoma Multiforme
    From Alpha Tau Medical Ltd.
    Via GlobeNewswire
    News headline image
    Alpha Tau Treats First Patient with Recurrent Lung Cancer
    From Alpha Tau Medical Ltd.
    Via GlobeNewswire
    News headline image
    Alpha Tau Announces FDA Approval of IDE to Initiate Multi-Center Investigator-Initiated Study of Alpha DaRT® in Immunocompromised Patients with Recurrent cSCC
    -Trial to focus on particularly vulnerable subset of patients, following strong clinician interest in use of the Alpha DaRT in this patient population - 
    From Alpha Tau Medical Ltd.
    Via GlobeNewswire
    News headline image
    Alpha Tau Announces Publication in Cancers Journal of Long-Term Safety and Efficacy Data in Multiple Hard-to-Treat Superficial Cancers
    From Alpha Tau Medical Ltd.
    Via GlobeNewswire
    News headline image
    Alpha Tau Announces Alpha DaRT Treatment of First Patient with Liver Metastases of Colorectal Cancer
    From Alpha Tau Medical Ltd.
    Via GlobeNewswire
    News headline image
    Alpha Tau to Present at the 42nd Annual J.P. Morgan Healthcare Conference
    From Alpha Tau Medical Ltd.
    Via GlobeNewswire
    News headline image
    Alpha Tau Announces Highly Promising Interim Results from Safety and Feasibility Trial of Alpha DaRT Treatment of Advanced Pancreatic Cancer
    From Alpha Tau Medical Ltd.
    Via GlobeNewswire
    News headline image
    Alpha Tau Submits to Japanese PMDA for Pre-Market Approval of Alpha DaRT in Patients with Recurrent Head and Neck Cancer
    From Alpha Tau Medical Ltd.
    Via GlobeNewswire
    News headline image
    Alpha Tau Enters Into Long-Term Lease of Site in New Hampshire for Second U.S. Manufacturing Facility
    From Alpha Tau Medical Ltd.
    Via GlobeNewswire
    News headline image
    Former U.S. Commissioner of Food and Drug Administration Stephen M. Hahn, M.D. Appointed to Alpha Tau Advisory Board
    From Alpha Tau Medical Ltd.
    Via GlobeNewswire
    News headline image
    Alpha Tau Treats First Patient with Advanced Inoperable Pancreatic Cancer at Israel’s Hadassah Medical Center
    From Alpha Tau Medical Ltd.
    Via GlobeNewswire
    News headline image
    Alpha Tau Announces Robust Long-Term Safety and Efficacy Data from Multiple Clinical Trials of Alpha DaRT
    From Alpha Tau Medical Ltd.
    Via GlobeNewswire
    News headline image
    Alpha Tau Expands its Alpha DaRT Treatment to Vulvar Cancer in Novel Clinical Trial with Cambridge University
    -First patient treated in the feasibility and safety study of intratumoral diffusing alpha-emitters radiation therapy (Alpha DaRT) for the treatment of new and recurrent squamous cell carcinoma of the... 
    From Alpha Tau Medical Ltd.
    Via GlobeNewswire
    News headline image
    Alpha Tau Announces the Publication of its US Multicenter Pilot Skin Cancer Trial Results in JAMA Network Open
    From Alpha Tau Medical Ltd.
    Via GlobeNewswire
    News headline image
    Alpha Tau and the JGH Announce Alpha DaRT Treatment of First Patient in its Advanced Pancreatic Cancer Clinical Trial
    First patient treated in the feasibility and safety study of intratumoral diffusing alpha radiation emitters for the treatment of advanced inoperable pancreatic cancer. 
    From Alpha Tau Medical Ltd.
    Via GlobeNewswire
    News headline image
    Alpha Tau Announces Alpha DaRT™ Treatment of First Two Patients in its Pivotal Multicenter Recurrent Skin Cancer (ReSTART) Trial
    From Alpha Tau Medical Ltd.
    Via GlobeNewswire
    < Previous 1 2 Next >
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.